

# Thermo Scientific Accell siRNA - Achieving Long-term Gene Silencing

Zaklina Strezoska and Christina Yamada, Thermo Fisher Scientific, Lafayette, CO, USA

## Abstract

Developing a thorough understanding of a gene's contribution to a particular phenotype is problematic when the protein has an extended half life or the phenotype under study requires days to materialize. Under these circumstances, reagents that induce long-term gene knockdown are needed to sufficiently deplete internal cellular stores for extended periods of time. To address this need, Thermo Fisher Scientific has now developed Thermo Scientific Accell siRNA, with novel modifications enabling uptake by cells without the aid of lipid transfection reagents. This innovative delivery technology allows repeated application of Accell® siRNA to provide extended-duration gene knockdown with only minimal effects on cell viability and the innate immune response. These attributes will greatly broaden the range of biological questions and cell types that can be investigated by researchers using RNAi.

## Introduction

Over the years, gene silencing by RNAi has relied heavily on the use of cationic lipid-based delivery reagents for transfecting cells with small interfering RNAs (siRNAs). In many cases, lipid-based transfection is sufficient and provides efficient levels of gene knockdown. Yet in a significant fraction of cases, cells are either refractory to lipid-mediated delivery of siRNAs or adversely sensitive to the presence of lipids.

The Accell siRNA product line

represents a recently developed technology that promotes delivery of siRNA independent of viral vectors or lipid-based transfection reagents (also referred to as “passive delivery”) to virtually any cell type. Through the incorporation of a unique combination of chemical and bioinformatic enhancements that increase functionality, stability, and lipid-independent delivery, Accell siRNAs can be used in a wide range of human, mouse, and rat cell lines that have been traditionally identified as difficult to transfect. (see Appendix I for a list of cells into which Accell siRNAs have been successfully tested). This novel delivery technology permits gene silencing with minimal off-target events (as assessed by genome-wide profiling), has limited repercussions on cell viability, and triggers a negligible innate immune response as assessed by quantitation of nine inflammatory response proteins using the SearchLight Array platform (Human Inflammatory Cytokine Array 1; Pierce product # 84619). Thus, unlike electroporation, which is historically the first alternative delivery method for cells found to be averse to lipid-based transfection reagents, Accell siRNA can be employed without significant effects on cell physiology.

Over the course of investigations, it is often necessary to knock down gene expression for extended periods of time to accurately assess the contribution of a particular protein to a given biological event. Long-term reduction of gene

expression can be problematic, particularly in cases where there are large intracellular reservoirs of the target or the half-life of the protein is drawn out. In some instances, researchers have attempted multiple, consecutive lipid-mediated transfections of siRNAs into cultured cells. Unfortunately, this approach is frequently cytotoxic and can induce brief (24-72 hrs) changes in the state of the innate immune response. To overcome these barriers, DNA-mediated RNAi, commonly exploiting viral delivery platforms, has been adopted. This approach can be successful, but is costly and requires significant development time. For a solution that requires neither lipid transfection nor viral delivery, this Application Note provides details of




Figure 1. Repeated Application workflow for inducing long-term gene knockdown in cultured cell lines. Following the initial plating in growth media (media plus serum, supplements and antibiotics), cells are treated with Accell siRNA resuspended in the Accell delivery media (Dharmacon Cat # B-005000-100). After 24-48 hrs, the delivery mix is replaced with complete media until cells are confluent, upon which the cultures are split and Accell delivery mix is re-applied.

how Accell siRNA may be applied to provide long-term knockdown of gene expression.

### Workflow for Long-term Gene Knockdown Using Accell siRNA

Figure 1 provides an overview of how Accell siRNA can be used to induce gene knockdown for extended periods of time. The day after cells are trypsinized, counted, and plated, the growth media used to culture cells (containing serum, supplements and antibiotics) is replaced with Accell delivery media containing Accell siRNA targeting the gene of interest (referred to as the Accell delivery mix). Passive transfection then proceeds for 24-48 hrs, whereupon the Accell delivery mix is exchanged for growth media, and cells are cultured for an additional period (generally 24-48 hrs). Prior to reaching confluency, cultures are split, re-plated, and treated again using the same protocol described in the previous round. If cells require additional time prior to splitting, they may be treated again with Accell delivery mix without splitting. This may vary depending upon the cell type, however the cycling between growth media and Accell delivery mix can be performed with little affect on cell viability to provide long-term gene knockdown in your cell type of choice.

### Demonstration of Long-term Gene Knockdown Using Accell siRNA Targeting PPIB

To demonstrate the feasibility of providing long-term gene knockdown using Accell technology, the workflow described above was employed to target the housekeeping gene PPIB (Cyclophilin B, NM\_000942) in SH-SY5Y neuroblastoma cells. Accell siRNA targeting PPIB was delivered at one of three concentrations (100 nM, 500 nM, or 1  $\mu$ M) and the levels of mRNA knockdown were assessed using branched DNA (bdNA; Panomics) on days 3, 7, 11, 15, and 19. Accell Non-targeting Control siRNA #1 was included to assess the specificity and overall effects of the treatment

on cell viability. Finally, at each passage, untreated cells subjected to media changes and splitting were treated with Accell siRNA targeting GAPDH as a control for transfectability of the cells.

The results of these experiments are presented in Figure 2 and demonstrate the efficacy of Accell technology in providing long-term gene knockdown. Accell siRNA-mediated gene knockdown of PPIB exhibited a dose-dependent response, with 1  $\mu$ M concentrations providing greater than 70% reduction in gene expression in

SH-SY5Y cells. Equally important, knockdown was specific while cell viability generally remained at 80% over the course of the 5 passages (19 days). The repeated application workflow was also optimized for HeLa cells, resulting in a 30-day duration of silencing (Figure 3).

### Compatibility of Accell Technology with Lipid-mediated Delivery

To test whether long-term gene knockdown using Accell siRNA was compatible with subsequent lipid-mediated siRNA transfections, HeLa cells treated over the course of 10 days with an Accell PPIB




Figure 2. Demonstration of long-term gene knockdown using Accell siRNA technology. SH-SY5Y neuroblastoma cells were plated at a density of 5K cells per well (96 well plate) and cultured overnight. The following day, the complete media was exchanged with the Accell delivery mix containing Accell siRNA targeting housekeeping genes PPIB at 0.1, 0.5 and 1  $\mu$ M or GAPDH at 1  $\mu$ M. Accell Non-targeting siRNA #1 (NTC: Dharmacon Cat #D-001910-01-05) was also used at 0.1, 0.5 and 1  $\mu$ M concentrations at every passage. After 48 hrs, the overlying delivery mix was replaced with complete media. Target knockdown (a) and cell viability (b) was assessed on days 3, 7, 11, 15, and 19 using bdNA (Panomics) and alamarBlue (BioSource, Intl) respectively. (UT – Untransfected control cells that have gone through the same procedure of media changes as Accell-treated cells).




Figure 3. Demonstration of long-term gene knockdown using Accell siRNA technology. HeLa cells were plated at a density of 10K cells per well (96-well plate) and cultured overnight. The following day, the complete media was exchanged with the Accell delivery mix containing 1  $\mu$ M Accell siRNA targeting the housekeeping gene PPIB. Accell Non-targeting siRNA #1 (Dharmacon Cat #D-001910-01-05) was also used at 1  $\mu$ M concentrations at every passage. Following 24 hours of treatment, the delivery mix was replaced with complete media. This workflow (Figure 1) was repeated, and target knockdown and cell viability were assessed on days 2, 6, 10, 14, 18, 22, 26, and 30 using bDNA (Panomics) and alamarBlue (BioSource, Intl) respectively.




Figure 4. Compatibility of Accell siRNA technology with alternative delivery methods. HeLa cells were treated with 1  $\mu$ M Accell PPIB siRNA over the course of three passages (10 days) as described. On day 10, cells were split, re-plated and transfected with GAPDH-targeting siRNA (100nM, Cat # D-001140-01-05) using DharmaFECT 1 transfection reagent (DF1; Dharmacon Cat # T-2001-01). Twenty-four hours after lipid-mediated transfection, the expression levels of PPIB and GAPDH were assessed using branched DNA technologies.

targeting siRNA were thereafter transfected with an siGENOME<sup>®</sup> (unmodified) siRNA targeting GAPDH and delivered via DharmaFECT<sup>®</sup> 1 transfection reagent. The results of these experiments are presented in Figure 4, and show that passive delivery using Accell siRNA technology is compatible with standard lipid transfection techniques. In cases where cells were treated with both the Accell PPIB siRNA and the siGENOME GAPDH siRNA delivered by DharmaFECT 1, overall knockdown for each gene was 80% or greater (day 13). These studies attest to the flexibility of experimental design when using Accell siRNA and demonstrate the ability to achieve multi-gene knockdown when using Accell siRNA in conjunction with lipid-mediated delivery techniques.

### Summary

While application of Accell siRNA for short-term gene knockdown requires little optimization, variations should be tested to identify the best protocol for long-term gene silencing in your cell type. Incorporation of controls that allow for assessment of the effects of passive delivery on cell viability and overall physiology are considered prudent to ensure that repeated exposure to Accell delivery mix does not introduce unwanted changes in the cell's phenotypic state.

Long-term gene knockdown is essential when protein stability and/or assay design requires sustained silencing. As demonstrated above, repeated application with the Accell delivery mix resulted in continuous silencing for up to 30 days. The described workflow is relatively non-toxic and compatible with lipid-mediated transfection (thus allowing multi-gene or combinatorial knockdown). This novel passive delivery technology significantly expands the experimental design options of researchers by permitting the use of cells that are historically refractory to lipid-mediated transfection.

## Appendix I. Cell Types Successful with Accell siRNA

<i>Human adherent cell lines (24)</i>					
SH-SY5Y	IMR32	LAN5	293T	A549	U87MG
LNCap	A-375	HeLa	HeLa S3	MIA PaCa-2	HEK293
MCF-7	MCF-10A	SK-BR3	OVCAR-3	NCI/ADR-RES	U2OS
Huh7	GTM-3	DU145	HT1080	HepG2	DLD-1
<i>Mouse and rat cell lines (7)</i>					
NIH 3T3	ES-D3	PC-12	3T3 L1	H9c2	C2C12
Rat2					
<i>Human suspension cell lines (4)</i>					
Jurkat	IM-9	THP-1	PBMC		
<i>Human differentiated stem cells (2)</i>					
Osteoblasts and adipocytes derived from hMSC					
<i>Human, mouse, and rat primary cells (9)</i>					
HUVEC	HUASMC	hMSC	Primary human astrocytes	primary human keratinocytes	primary human T-cells
Primary mouse hepatocytes		Primary rat cortical neurons		primary rat striatum neurons	
<i>Cell types that failed Accell siRNA application (0)</i>					

Please check [www.thermo.com/accell](http://www.thermo.com/accell) for the most up-to-date information.

### Troubleshooting

For technical information or troubleshooting contact Thermo Scientific Genomics Tech Support:

In North America (US, Canada, Central/South America)

Techservice.genomics@thermofisher.com

+1 (800) 235-9880

In Europe (EU, Middle East, Africa)

Techservice.emea.genomics@thermofisher.com

(+44) 1372 840410

In Other Countries

[www.thermoscientific.com/dharmacondistributors](http://www.thermoscientific.com/dharmacondistributors)

Copyright © 2011 Thermo Fisher Scientific, Inc. All Rights Reserved.

The product(s) described herein ("Products") are protected by patents, pending patents and other intellectual property owned or licensed by Dharmacon Inc. as set forth in Dharmacon's Terms and Conditions (found at [www.thermoscientific.com/dharmacon](http://www.thermoscientific.com/dharmacon) or included with the Products when sold). By using the Product(s), users accept the Terms and Conditions, which expressly govern all use of the Product(s). The Product(s) are intended solely for research use and not for diagnostic, clinical or therapeutic uses. All other trademarks are the property of Thermo Fisher Scientific Inc. and its subsidiaries.

Literature Code: 00178-08-C-01-U